A Genetic Screen Identifies TCF3/E2A and TRIAP1 as Pathway-Specific Regulators of the Cellular Response to p53 Activation

Cell Reports

Volumn 3, Issue 5, 2013, Pages 1346-1354

  Andrysik, Zdenek ^a   Kim, Jihye ^b   Tan, Aik Choon ^b   Espinosa, Joaquín M ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; INHIBITOR OF APOPTOSIS PROTEIN; MESSENGER RNA; PROTEIN P53; PUMA PROTEIN; TP53 REGULATED INHIBITOR OF APOPTOSIS; TRANSCRIPTION FACTOR E2A; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BBC3 PROTEIN, HUMAN; ONCOPROTEIN; RNA POLYMERASE II; SIGNAL PEPTIDE; SMALL INTERFERING RNA; TFPT PROTEIN, HUMAN; TRIAP1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CONTROLLED STUDY; CYCLIN DEPENDENT KINASE INHIBITOR 1A GENE; GENE EXPRESSION; GENE LOCUS; GENETIC SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PUMA GENE; SIGNAL TRANSDUCTION; TRANSACTIVATION; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; DNA DAMAGE; GENETICS; HCT116 CELL LINE; METABOLISM; RNA INTERFERENCE; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; HCT116 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; RNA POLYMERASE II; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84878538147     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.04.014     Document Type: Article

References (26)

1. Altura R.A., Inukai T., Ashmun R.A., Zambetti G.P., Roussel M.F., Look A.T. The chimeric E2A-HLF transcription factor abrogates p53-induced apoptosis in myeloid leukemia cells. Blood 1998, 92:1397-1405.
2. Beckerman R., Donner A.J., Mattia M., Peart M.J., Manley J.L., Espinosa J.M., Prives C. A role for Chk1 in blocking transcriptional elongation of p21 RNA during the S-phase checkpoint. Genes Dev. 2009, 23:1364-1377.
3. Brown C.J., Lain S., Verma C.S., Fersht A.R., Lane D.P. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 2009, 9:862-873.
4. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
5. de Pooter R.F., Kee B.L. E proteins and the regulation of early lymphocyte development. Immunol. Rev. 2010, 238:93-109.
6. Echeverri C.J., Beachy P.A., Baum B., Boutros M., Buchholz F., Chanda S.K., Downward J., Ellenberg J., Fraser A.G., Hacohen N., et al. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat. Methods 2006, 3:777-779.
7. Engel I., Johns C., Bain G., Rivera R.R., Murre C. Early thymocyte development is regulated by modulation of E2A protein activity. J.Exp. Med. 2001, 194:733-745.
8. Gomes N.P., Espinosa J.M. Disparate chromatin landscapes and kinetics of inactivation impact differential regulation of p53 target genes. Cell Cycle 2010, 9:3428-3437.
9. Gomes N.P., Bjerke G., Llorente B., Szostek S.A., Emerson B.M., Espinosa J.M. Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. Genes Dev. 2006, 20:601-612.
10. Greenbaum S., Lazorchak A.S., Zhuang Y. Differential functions for the transcription factor E2A in positive and negative gene regulation in pre-B lymphocytes. J.Biol. Chem. 2004, 279:45028-45035.
11. Henry R.E., Andrysik Z., París R., Galbraith M.D., Espinosa J.M. A DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX. EMBO J. 2012, 31:1266-1278.
12. Kim J., Tan A.C. BiNGS!SL-seq: a bioinformatics pipeline for the analysis and interpretation of deep sequencing genome-wide synthetic lethal screen. Methods Mol. Biol. 2012, 802:389-398.
13. Murre C., McCaw P.S., Baltimore D. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 1989, 56:777-783.
14. París R., Henry R.E., Stephens S.J., McBryde M., Espinosa J.M. Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation. Cell Cycle 2008, 7:2427-2433.
15. Park W.R., Nakamura Y. p53CSV, a novel p53-inducible gene involved in the p53-dependent cell-survival pathway. Cancer Res. 2005, 65:1197-1206.
16. Patel D., Chaudhary J. Increased expression of bHLH transcription factor E2A (TCF3) in prostate cancer promotes proliferation and confers resistance to doxorubicin induced apoptosis. Biochem. Biophys. Res. Commun. 2012, 422:146-151.
17. Prabhu S., Ignatova A., Park S.T., Sun X.H. Regulation of the expression of cyclin-dependent kinase inhibitor p21 by E2A and Id proteins. Mol. Cell. Biol. 1997, 17:5888-5896.
18. Riley T., Sontag E., Chen P., Levine A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 2008, 9:402-412.
19. Semerad C.L., Mercer E.M., Inlay M.A., Weissman I.L., Murre C. E2A proteins maintain the hematopoietic stem cell pool and promote the maturation of myelolymphoid and myeloerythroid progenitors. Proc. Natl. Acad. Sci. USA 2009, 106:1930-1935.
20. Sullivan K.D., Gallant-Behm C.L., Henry R.E., Fraikin J.L., Espinosa J.M. The p53 circuit board. Biochim. Biophys. Acta 2012, 1825:229-244.
21. Sullivan K.D., Padilla-Just N., Henry R.E., Porter C.C., Kim J., Tentler J.J., Eckhardt S.G., Tan A.C., DeGregori J., Espinosa J.M. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nat. Chem. Biol. 2012, 8:646-654.
22. Tovar C., Rosinski J., Filipovic Z., Higgins B., Kolinsky K., Hilton H., Zhao X., Vu B.T., Qing W., Packman K., et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl. Acad. Sci. USA 2006, 103:1888-1893.
23. Vousden K.H., Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009, 137:413-431.
24. Yan W., Young A.Z., Soares V.C., Kelley R., Benezra R., Zhuang Y. High incidence of T-cell tumors in E2A-null mice and E2A/Id1 double-knockout mice. Mol. Cell. Biol. 1997, 17:7317-7327.
25. Yu J., Wang Z., Kinzler K.W., Vogelstein B., Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:1931-1936.
26. Zhuang Y., Soriano P., Weintraub H. The helix-loop-helix gene E2A is required for B cell formation. Cell 1994, 79:875-884.